AzTrials
AzTrials

Anxiety DisordersPHYSBINCT03247270

Physical Fitness and Brain - Interventional Study

A study testing Intervention I and Intervention II in people with Anxiety Disorders, run by Göteborg University at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

According to the Global Burden of Disease report in 2015, anxiety disorders are among the top 10 contributors to years lived with disability worldwide. There is a need for effective treatment protocols. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Anxiety Disorders
What is being tested?
Intervention I and Intervention II
Could I receive a placebo?
No, everyone receives an active treatment
How many people
168 participants
Where
1 siteSweden
Study dates
21 Aug 2017to 30 Jun 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Panic syndrome (F41.0)
  • Generalized anxiety (F41.1)
  • Mixed anxiety- and depression conditions (F41.2 and F41.3)
  • Anxiety UNS (F41.9)

Who cannot join

  • Physical difficulties in performing a physical exercise program
  • Pathological ECG
  • Previous psychiatric illnesses
  • Ongoing abuse
  • Increased risk of suicide as determined by the GP
  • Pregnant women
  • Physical activity level at baseline exceeding one exercise occasion per week.
  • Ongoing psychotherapy

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Department of Public Health and Community Medicine

    Gothenburg

Other trials in Sweden

About this study

Official title: Physical Fitness and Brain - Interventional Study of the Importance of Physical Fitness on Symptoms of Anxiety, Cognitive Ability and Sick Leave, in Primary Care.

According to the Global Burden of Disease report in 2015, anxiety disorders are among the top 10 contributors to years lived with disability worldwide. There is a need for effective treatment protocols. As cardiovascular fitness has a major impact on the brain's ability to change structurally and functionally, interventions involving physical exercise might prove positive in the treatment of persons with anxiety. Yet there are few high quality clinical studies with physical exercise as an intervention for anxiety disorders.

Aims:

Read more
  1. To test a 12 week physical exercise intervention for persons treated for anxiety disorders within primary care. The exposure of interest is intensity of physical exercise; outcomes include anxiety symptom burden, cognitive ability and sick leave.
  2. To gain knowledge regarding potential mechanisms by comparing serum levels of specific hormones and cytokines (characterized and associated with brain plasticity in animal models) before and after different intensities of exercise.

Implementation:

Patients will be randomized into 3 groups: 1) Intervention I: 12 week exercise program with low-intensity fitness training 3 times per week. 2) Intervention II: 12 week exercise program with moderate to high-intensity fitness training 3 times per week. 3) Control group, who will have a physiotherapy session once and will be given general advice about physical activity. At baseline, 12 weeks and 1 year data of cardiovascular fitness, anxiety symptoms, cognitive and working ability and biomarkers will be collected.

Impact:

If physical exercise positively affects anxiety disorders it would have significance, for the patients as well as for society. In addition to increased quality of life, it may decrease future marginalization and premature death among individuals suffering from anxiety disorders. Reducing medical and sick-leave costs would also liberate health care resources to be used elsewhere in an economically strained health care system.

Read the detailed description

Overall objective To examine whether physical exercise reduces anxiety symptoms, improves cognition and decreases need of sick leave in patients with anxiety disorders in primary care.

Background Mental illness is the most common reason for unemployment in people of working age and this is a growing patient group in Swedish primary care today. A survey by the European Commission showed that 17% of the Swedish population had sought help over the past year for psychiatric problems. These figures are above average for European countries and are increasing. Sweden's costs for mental illness is around MSEK 70,000 annually - an increase of MSEK 20,000 over ten years - and the proportion of sick leave days due to a psychiatric diagnosis is currently 40%. Mental illness reduces quality of life substantially. For example, 18-year-olds with anxiety disorders have increased risk of future marginalization and have a two-fold increase in mortality not only due to suicide but several different death causes, emphasizing the importance of finding effective treatment strategies.

The ability of the adult brain to change both structurally and functionally is called brain plasticity. Both in humans and in animal models physical exercise has a major impact on brain plasticity. Physical exercise can increase neurogenesis and improve memory functions in rats, and circulating insulin-like growth factor I (IGF-I) can promote this effect. Brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) are also involved. In addition, there is evidence that physical activity modifies neuronal activity, increases the formation of synapses, and reduces inflammation markers, which may be correlated with neuroprotection.

The investigators have previously demonstrated an association between physical fitness and anxiety disorders, suggesting positive preventive benefits of physical exercise. The beneficial effects of exercise interventions have to date mainly been demonstrated in persons with depression.

The specific aims of this project are:

  1. To test a 12 week physical exercise intervention for persons treated for anxiety disorders within primary care. The exposure of interest is intensity of physical exercise; outcomes include anxiety symptom burden, cognitive ability and sickness leave.
  2. To gain knowledge regarding potential mechanisms by comparing serum levels of specific hormones (characterized and associated with brain plasticity in animal models) before and after different intensities of exercise.

Relationship to the research frontline In contrast to the literature on depression there are very few clinical studies on physical exercise as an intervention for anxiety. All six trials performed hitherto were identified as being at a high risk of bias. Higher quality trials are thus required. There is a need to investigate the role of intensity, volume, frequency and type of exercise on anxiety symptoms, cognitive function and working ability in people with anxiety disorders. Also, the putative mechanisms behind the potential effects on anxiety symptoms are not elucidated and deserve attention.

A novel feature of this study is the examination of different intensities of physical fitness-improving exercise in patients with anxiety disorders. This has not previously been performed and would yield valuable insight into dose-response associations between physical fitness and effects on the brain. Objective measurements of physical fitness and cognition are a great strength of the proposed study. Analyzing specific hormones and cytokines before and after the intervention, in relation to symptoms and functional data, may provide additional information about mechanistic aspects, treatment effect and prognosis. The proposed research also offers opportunities to develop effective treatment protocols to reduce the costs of sick-leave, an area of increasing interest world-wide.

In summary, the proposed study has the potential to provide novel and important contributions to existing scientific knowledge regarding how physical exercise influences anxiety, cognitive function and working ability in patients with anxiety disorders in primary care.

Work plan The study cohort will be patients diagnosed with anxiety disorders at six primary care centres in Gothenburg, Southern Bohuslän and Halland including patients with panic syndrome (F41.0), generalized anxiety (F41.1), mixed anxiety- and depression conditions (F41.2 and F41.3), as well as anxiety UNS (F41.9). Diagnoses and comorbidities will be determined by the study psychiatrist using the M.I.N.I (the Mini International Neuropsychiatric Interview, Swedish version 6.0.0d DSM-IV). Intervention and follow-ups will take place at Primary Care Rehab.

The investigators will exclude patients from the baseline who have physical difficulties in performing a physical exercise program, pathological ECG, previous psychiatric illnesses, ongoing abuse, increased risk of suicide as determined by the GP, those under 18, pregnant women and those over 65 years of age. An additional exclusion criterion will be physical activity level at baseline exceeding one exercise occasion per week. Both people with and without ongoing treatment with psychoactive medication will be included. Supportive contact for example with a health center nurse is not an exclusion criterion but persons with ongoing psychotherapy will not be included unless the participants, as well as the GP, are willing to take a break in therapy for the duration of the 12 week study.

Recruitment takes place at primary care centres and thus represents the individuals who seek help in primary care for anxiety. Potential participants are contacted by a study psychiatrist who has no healthcare provider relationship to the patient. Intervention and follow-ups will take place at Primary Care Rehab. Each individual must sign a statement of informed consent.

At baseline, 12 weeks and 1 year, the following data will be collected by the study physician:

  • MINI International Neuropsychiatric Interview (Swedish version 6.0.0d DSM-IV)
  • Use of psychoactive prescription drugs including dosage and duration
  • Sick leave
  • Blood pressure
  • BMI
  • Self-report questions about alcohol (AUDIT self-assessment scale), smoking and diet
  • Established psychiatric self-assessment scales: Beck Anxiety Inventory (BAI), Montgomery Åsberg Depression Rating Scale (MADRAS) and the quality of life instrument EQ-5D.
  • Test Design Fluency, which is part of the D-Kefs battery of tests and is well known and used by many psychologists within education and psychiatry. This is a standardized test, carried out within a few minutes that measures executive abilities such as creativity, response inhibition and cognitive flexibility.
  • Objective measurements of physical fitness in the form of estimated maximal oxygen uptake capacity (VO2max) using Åstrand's submaximal bicycle test.
  • Blood samples will be taken, by a nurse at the health center, to analyze the potential correlation of the following hormones/cytokines with symptoms and function data: S-IGF-I, S-BDNF, S-VEGF and high sensitivity CRP. The blood samples are stored in a separate, locked -70 freezer at c-lab Sahlgrenska. IVO has been notified of the establishment of a biobank (No 946).

Patients will be randomized into three groups: 1) Intervention I: 12 week exercise program with low-intensity fitness training 3 times per week. 2) Intervention II: 12 week exercise program with moderate to high-intensity fitness training 3 times per week. 3) Control group. The physiotherapists at Primary Care Rehab will perform the submaximal bicycle test and personally design the exercise program in the gym. The patients will have a one-to-one session with the physiotherapists on 2 occasions and afterwards several people will exercise at the same time in the gym.

A statistical power analysis has been performed by statistician Linus Schiöler. Based on other studies, an effect size of 0.5 difference between the groups is clinically relevant, which equates to a 5 point difference between the groups using the BAI scale. Standard deviations from a previous study using BAI as the outcome measurement were in the interval of 5-10. SD 9 was used in the calculations. Based on these assumptions, at least 60 patients in each of the treatment arms should be included to reach 80% power at the 5% significance level. Health-economic analyses will be performed using primary data generated within the project concerning health-related quality of life effects caused by the intervention and information about healthcare resources utilized. A health-economic model that depicts the clinical trial will be constructed and used for computing cost-utility measures. Moreover, the model will be constructed for performing extensive probabilistic sensitivity analyses.

Ethical considerations The Ethics Committee of the University of Gothenburg approved the study: PHYSBI intervention study: EPN Göteborg Dnr: 300-16. The control group will have a physiotherapy session once and will be given general advice about physical activity. There will be a possibility to individualize treatments i.e. the same intensity but different exercises to better fit the needs and preferences of different individuals. Coding and anonymization of data occur after data collection is complete.

Collaborations The principal investigator for this project Ass Prof Maria Åberg is the chair of the steering committee for Physical Fitness and Brain Epidemiological studies (PHYSBE) which is a multidisciplinary umbrella organization for several projects. Prof Kjell Torén from Occupational and Environmental Medicine provides epidemiological competence. Prof Margda Waern provides psychiatric expertise. Physiotherapist Louise Danielsson and Prof Kristian Bolin at the Department of Economics and Statistics have experience of clinical intervention studies.

The results will be published in international renowned peer-reviewed research journals.

Being tested
Intervention I, Intervention II
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intervention IBehavioural

    Low intensive physical exercise

  • Intervention IIBehavioural

    High intensive physical exercise

Study groups in NCT03247270
Study groupRoleWhat they receive
Intervention IExperimentalPhysical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
Receives: Behavioral: Intervention I
Intervention IIExperimentalPhysical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
Receives: Behavioral: Intervention II
Control groupNo interventionControl group, who will have a physiotherapy session once and will be given general advice about physical activity.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Anxiety symptom burden

    Established psychiatric self-assessment scales: BAI

    Measured: 12 weeks after baseline

  2. Anxiety symptom burden

    Established psychiatric self-assessment scales: BAI

    Measured: 1 year after baseline

  3. Anxiety symptom burden

    Established psychiatric self-assessment scales: MADRS-S

    Measured: 12 weeks after baseline

  4. Anxiety symptom burden

    Established psychiatric self-assessment scales: MADRS-S

    Measured: 1 year after baseline

  5. Anxiety symptom burden

    Established psychiatric self-assessment scales: EQ-5D

    Measured: 12 weeks after baseline

  6. Anxiety symptom burden

    Established psychiatric self-assessment scales: EQ-5D

    Measured: 1 year after baseline

  7. Cognitive ability

    Test Design Fluency, which is part of the D-Kefs battery of tests

    Measured: 12 weeks after baseline

  8. Cognitive ability

    Test Design Fluency, which is part of the D-Kefs battery of tests

    Measured: 1 year after baseline

  9. Cognitive ability

    Digit test included in WAIS test battery

    Measured: 12 weeks after baseline

  10. Cognitive ability

    Digit test included in WAIS test battery

    Measured: 1 year after baseline

  11. Sick leave

    Questionnaire

    Measured: 12 weeks after baseline

  12. Sick leave

    Questionnaire

    Measured: 1 year after baseline

  13. Biomarkers in serum

    S-IGF-I

    Measured: 12 weeks after baseline

  14. Biomarkers in serum

    S-IGF-I

    Measured: 1 year after baseline

  15. Biomarkers in serum

    S-BDNF

    Measured: 12 weeks after baseline

  16. Biomarkers in serum

    S-BDNF

    Measured: 1 year after baseline

  17. Biomarkers in serum

    S-VEGF

    Measured: 12 weeks after baseline

  18. Biomarkers in serum

    S-VEGF

    Measured: 1 year after baseline

  19. Biomarkers in serum

    S-high sensitivity CRP

    Measured: 12 weeks after baseline

  20. Biomarkers in serum

    S-high sensitivity CRP

    Measured: 1 year after baseline

  21. Biomarkers in serum

    S-irisin

    Measured: 12 weeks after baseline

  22. Biomarkers in serum

    S-irisin

    Measured: 1 year after baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Aug 2017
  2. Study start21 Aug 2017
  3. Primary completion30 Jun 2021
  4. Study completion30 Jun 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
RCT
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
168 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03247270
Sponsor's protocol ID
Dnr300-16
Acronym
PHYSBI
Status last verified
Aug 2021
First submitted
4 Aug 2017
Last updated
3 Aug 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Love J, Hensing G, Soderberg M, Toren K, Waern M, Aberg M. Future marginalisation and mortality in young Swedish men with non-psychotic psychiatric disorders and the resilience effect of cognitive ability: a prospective, population-based study. BMJ Open. 2016 Aug 10;6(8):e010769. doi: 10.1136/bmjopen-2015-010769.

    PubMed 27515748
  • Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nat Rev Neurosci. 2008 Jan;9(1):58-65. doi: 10.1038/nrn2298.

    PubMed 18094706
  • Aberg MA, Aberg ND, Palmer TD, Alborn AM, Carlsson-Skwirut C, Bang P, Rosengren LE, Olsson T, Gage FH, Eriksson PS. IGF-I has a direct proliferative effect in adult hippocampal progenitor cells. Mol Cell Neurosci. 2003 Sep;24(1):23-40. doi: 10.1016/s1044-7431(03)00082-4.

    PubMed 14550766
  • Carro E, Nunez A, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci. 2000 Apr 15;20(8):2926-33. doi: 10.1523/JNEUROSCI.20-08-02926.2000.

    PubMed 10751445
  • Lee TMC, Wong ML, Lau BW, Lee JC, Yau SY, So KF. Aerobic exercise interacts with neurotrophic factors to predict cognitive functioning in adolescents. Psychoneuroendocrinology. 2014 Jan;39:214-224. doi: 10.1016/j.psyneuen.2013.09.019. Epub 2013 Sep 25.

    PubMed 24149089
  • Eliakim A, Oh Y, Cooper DM. Effect of single wrist exercise on fibroblast growth factor-2, insulin-like growth factor, and growth hormone. Am J Physiol Regul Integr Comp Physiol. 2000 Aug;279(2):R548-53. doi: 10.1152/ajpregu.2000.279.2.R548.

    PubMed 10938244
  • Kohut ML, McCann DA, Russell DW, Konopka DN, Cunnick JE, Franke WD, Castillo MC, Reighard AE, Vanderah E. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun. 2006 May;20(3):201-9. doi: 10.1016/j.bbi.2005.12.002. Epub 2006 Feb 28.

    PubMed 16504463
  • Stranahan AM, Martin B, Maudsley S. Anti-inflammatory effects of physical activity in relationship to improved cognitive status in humans and mouse models of Alzheimer's disease. Curr Alzheimer Res. 2012 Jan;9(1):86-92. doi: 10.2174/156720512799015019.

    PubMed 22329653
  • Aberg MA, Waern M, Nyberg J, Pedersen NL, Bergh Y, Aberg ND, Nilsson M, Kuhn HG, Toren K. Cardiovascular fitness in males at age 18 and risk of serious depression in adulthood: Swedish prospective population-based study. Br J Psychiatry. 2012 Nov;201(5):352-9. doi: 10.1192/bjp.bp.111.103416. Epub 2012 Jun 14.

    PubMed 22700083
  • Aberg MA, Nyberg J, Toren K, Sorberg A, Kuhn HG, Waern M. Cardiovascular fitness in early adulthood and future suicidal behaviour in men followed for up to 42 years. Psychol Med. 2014 Mar;44(4):779-88. doi: 10.1017/S0033291713001207. Epub 2013 Jun 6.

    PubMed 23739044
  • Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, McMurdo M, Mead GE. Exercise for depression. Cochrane Database Syst Rev. 2013 Sep 12;2013(9):CD004366. doi: 10.1002/14651858.CD004366.pub6.

    PubMed 24026850
  • Danielsson L, Papoulias I, Petersson EL, Carlsson J, Waern M. Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study. J Affect Disord. 2014 Oct;168:98-106. doi: 10.1016/j.jad.2014.06.049. Epub 2014 Jul 5.

    PubMed 25043321
  • Stubbs B, Vancampfort D, Rosenbaum S, Firth J, Cosco T, Veronese N, Salum GA, Schuch FB. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Res. 2017 Mar;249:102-108. doi: 10.1016/j.psychres.2016.12.020. Epub 2017 Jan 6.

    PubMed 28088704
  • Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893-7. doi: 10.1037//0022-006x.56.6.893. No abstract available.

    PubMed 3204199
  • Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.

    PubMed 444788

Questions about this trial

What is this clinical trial studying?

A study testing Intervention I and Intervention II in people with Anxiety Disorders, run by Göteborg University at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Anxiety symptom burden (time frame: 12 weeks after baseline). The study lists 22 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03247270, which also lists 19 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in